Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Phlebotomy × Myeloid × Clear all

Phase

Status

Completed 2 Unknown 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycythemia Vera 1 Myeloproliferative Disorders 1

Interventions

Specimen Handling 3 Azacitidine 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 Tacrolimus 2 Stem Cell Transplantation 2 venetoclax 1 trametinib 1 tagraxofusp 1 selinexor 1 pegylated granulocyte colony-stimulating factor 1 peginterferon alfa-2b 1 luspatercept 1 letermovir 1 flumatinib 1 fludarabine 1 dabrafenib 1 Spectroscopy, Near-Infrared 1 Single-Cell Gene Expression Analysis 1 Receptors, Antigen, T-Cell 1 Quality of Life 1 Pleurodesis 1 Phlebotomy 1 Observation 1 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1 Mycophenolic Acid 1 Mutation 1 Melphalan 1 Lymphatic Irradiation 1 Imatinib Mesylate 1 Idarubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06290765 2025-07-31

PV

PharmaEssentia

Phase 4 Not yet recruiting

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡